LexDanaLexDanabeta
Inventor

Hui Li

Inventor
Santa Clara, CA, US

Overview

171→
Patents
1996–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 171 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds30%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes23%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium12%
C07BGeneral methods of organic chemistry4%
Y02ATechnologies for adaptation to climate change1%
C12NMicroorganisms or enzymes1%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
C12YEnzymes1%
C07CAcyclic or carbocyclic compounds0%
PatentTitleYear
10,828,3012,4-pyrimidinediamine compounds and their uses202010,792,282Protein kinase C inhibitors and uses thereof202010,793,564Amino acid compounds and methods of use202010,709,7032,4-pyrimidinediamine compounds and their uses202010,696,672Amino acid compounds and methods of use202010,682,3502,4-pyrimidinediamine compounds and their uses202010,610,530Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile202010,604,520N-acyl amino acid compounds and methods of use202010,556,891Compositions and methods for inhibition of the JAK pathway202010,479,783Compositions and methods for inhibition of the JAK pathway201910,421,752Compositions and methods for inhibition of the JAK pathway201910,414,753Amide compounds and method for making and using201910,369,1482,4-pyrimidinediamine compounds and their uses201910,370,367IRAK inhibitors and method for making and using201910,314,8402,4-pyrimidinediamine compounds and their uses201910,316,045Substituted pyrrolo[3,4-c]pyrazoles as pkc kinase inhibitors2019RE047396Compositions and methods for inhibition of the JAK pathway201910,259,826Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds201910,208,075Pyrazole compounds and method for making and using the compounds201910,208,074Pyrazole compounds and method for making and using the compounds201910,125,150Crystalline forms of a PI3K inhibitor201810,016,429Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile201810,005,767Compositions and methods for inhibition of the JAK pathway201810,005,777Protein kinase C inhibitors and uses thereof20189,988,401Crystalline forms of a PI3K inhibitor20189,982,000Pyrazole compounds and method for making and using the compounds20189,920,041'Compositions and methods for inhibition of the JAK pathway'20189,913,842'2,4-pyrimidinediamine compounds and their uses'20189,751,893'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'20179,732,073'Compositions and methods for inhibition of the JAK pathway'20179,725,419'Cycloalkyl substituted pyrimidinediamine compounds and their uses'20179,682,976'Protein kinase C inhibitors and uses thereof'20179,611,260'Compositions and methods for inhibition of the JAK pathway'20179,598,432'2,4-pyrimidinediamine compounds and uses as anti-proliferative agents'20179,593,082'Compositions and methods for inhibition of the JAK pathway'20179,586,908'2,4-pyrimidinediamine compounds and their uses'20179,566,278'Protein kinase C inhibitors and uses thereof'20179,566,283'Compositions and methods for inhibition of the JAK pathway'20179,540,334'2,4-pyrimidinediamine compounds and their uses'20179,518,060'Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors'20169,505,719'Synthesis and use of kinase inhibitors'20169,499,493'2,4-pyrimidinediamine compounds and their uses'20169,481,654'Compositions and methods for inhibition of the JAK pathway'20169,464,088'Piperidin-4-yl azetidine derivatives as JAK1 inhibitors'20169,416,112'2,4-pyrimidinediamine compounds and their uses'20169,376,439'Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile'20169,346,765'2,4-pyrimidinediamine compounds and their uses'20169,321,763'Protein kinase C inhibitors and uses thereof'20169,248,190'Compositions and methods for inhibition of the JAK pathway'20169,248,132'Compositions and methods for inhibition of the JAK pathway'20169,169,249'Protein kinase C inhibitors and uses thereof'20159,162,989'2,4-Pyrimidinediamine compounds and their uses'20159,149,475'Protein kinase C inhibitors and uses thereof'20159,133,133'2,4-pyridinediamine compounds and their uses'20159,126,991'Radezolid salts and polymorphic forms thereof'20159,084,795'Compositions and methods for inhibition of the JAK pathway'20159,067,925'Compositions and methods for inhibition of the JAK pathway'20159,040,550'2,4-pyrimidinediamine compounds and their uses'20159,040,543'Compositions and methods for inhibition of the JAK pathway'20159,040,527'Pyrimidinediamine kinase inhibitors'20159,018,204'2,4-pyrimidinediamine compounds and their uses'20158,999,981'3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives'20158,993,585'Cyclic amine substituted pyrimidinediamines as PKC inhibitors'20158,962,643'Compositions and methods for inhibition of the JAK pathway'20158,877,761'N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors'20148,865,741'Aminoindane compounds and use thereof in treating pain'20148,853,397'2,4-pyrimidinediamine compounds and their uses'20148,835,430'2,4-pyrimidinediamine compounds and their uses'20148,829,013'Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile'20148,822,685'2,4-pyrimidinediamine compounds and their uses'20148,822,481'Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile'20148,815,848'Compositions and methods for inhibition of the JAK pathway'20148,809,341'2,4-pyrimidinediamine compounds and uses as anti-proliferative agents'20148,765,734'Piperidin-4-yl azetidine derivatives as JAK1 inhibitors'20148,735,400'Compositions and methods for inhibition of the JAK pathway'20148,729,087'Compositions and methods for inhibition of the JAK pathway'20148,722,693'Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile'20148,680,108'Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors'20148,575,165'Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds'20138,563,716'Compositions and methods for inhibition of the JAK pathway'20138,557,806'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'20138,546,398'Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses'20138,530,656'Compositions and methods for inhibition of the JAK pathway'20138,524,901'Compositions and methods for inhibition of the JAK pathway'20138,518,937'Pyrimidinediamine kinase inhibitors'20138,518,952'6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors'20138,507,005'Particulates of a CRTH2 antagonist'20138,420,659'Compositions and methods for inhibition of the JAK pathway'20138,415,365'Compositions and methods for inhibition of the JAK pathway'20138,410,093'Cycloalkyl substituted pyrimidinediamine compounds and their uses'20138,410,266'2,4-pyrimidinediamine compounds and their uses'20138,399,472'Compositions and methods for inhibition of the JAK pathway'20138,377,924'Protein kinase C inhibitors and uses thereof'20138,343,954'Compositions and methods for inhibition of the JAK pathway'20138,334,297'2,4-pyrimidinediamine compounds for treatment of inflammatory disorders'20128,334,296'2,4-pyrimidinediamine compounds and their uses'20128,324,200'Compositions and methods for inhibition of the JAK pathway'20128,304,422'Compositions and methods for inhibition of the JAK pathway'20128,299,087'Compositions and methods for inhibition of the JAK pathway'20128,283,479'CXCR2 inhibitors'20128,278,299'Pyrimidinediamine kinase inhibitors'20128,268,851'Compositions and methods for inhibition of the JAK pathway'20128,193,197'Compositions and methods for inhibition of the JAK pathway'20128,188,276'2,4-pyrimidinediamine compounds and their uses'20128,183,255'N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors'20128,178,671'Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds'20128,158,621'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'20128,148,525'2,4-pyrimidinediamine compounds and their uses'20128,114,871'3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives'20128,101,627'Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses'20128,044,054'Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses'20118,030,483'Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses'20118,008,501'Quinoline compounds and their uses'20117,947,698'Compositions and methods for inhibition of the JAK pathway'20117,919,628'CXCR2 inhibitors'20117,915,273'Compositions and methods for inhibition of the JAK pathway'20117,906,644'2,4-pyrimidinediamine compounds and their uses'20117,884,111'2,4-pyrimidinediamine compounds and uses as anti-proliferative agents'20117,868,013'Cycloalkyl substituted pyrimidinediamine compounds and their uses'20117,863,286'Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses'20117,858,633'Cycloalkyl substituted pyrimidinediamine compounds and their uses'20107,834,024'Compositions and methods for inhibition of the JAK pathway'20107,825,116'N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines'20107,820,819'2,4-pyrimidinediamine compounds and their uses'20107,812,029'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'20107,803,939'2,4-pyrimidinediamine compounds and their uses'20107,754,714'Cycloalkyl substituted pyrimidinediamine compounds and their uses'20107,655,797'Intermediates for making 2,4-pyrimidinediamine compounds'20107,642,351'2,4-Pyrimidinediamine compounds and their uses'20107,589,200'5-Fluoro-4N-phenyl-4-pyrimidineamine compounds'20097,582,648'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'20097,560,466'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'20097,557,210'2,4-pyrimidinediamine compounds and their uses'20097,550,460'2,4-pyrimidinediamine compounds and their uses'20097,521,560'2-substituted quinoline compounds and their uses'20097,517,886'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'20097,511,137'Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates'20097,498,435'2,4-pyrimidinediamine compounds and their uses'20097,491,732'Compositions and methods for inhibition of the JAK pathway'20097,485,724'2,4-pyrimidinediamine compounds and their uses'20097,452,879'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'20087,435,814'2,4-Pyrimidinediamine compounds and their uses'20087,384,921'Polymorphic forms of 6-11 bicyclic ketolide derivatives'20087,332,484'2,4-pyrimidinediamine compounds and their uses'20087,329,672'2,4-pyrimidinediamine compounds and their uses'20087,329,671'2,4-pyrimidinediamine compounds and their uses'20087,153,960'Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones'20067,122,542'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'20067,060,827'Intermediates useful for making 2,4-pyrimidinediamine compounds'20066,919,451'Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones'20056,750,233'Aromatic sulfone hydroxamic acid metalloprotease inhibitor'20046,747,158'Efficient process for the preparation of a factor Xa inhibitor'20046,683,077'2-Amino-benzoxazinones for the treatment of viral infections'20046,667,332'Efficient process for the preparation of a factor Xa inhibitor'20036,638,952'Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds'20036,610,858'Efficient method for the conversion of nitriles to amidines'20036,541,639'Efficient ligand-mediated Ullmann coupling of anilines and azoles'20036,465,656'Synthesis of 1,3,5-trisubstituted pyrazoles'20026,399,784'Efficient method for the conversion of nitriles to amidines'20026,380,189'2-amino benzoxazinones for the treatment of viral infections'20026,329,527'Synthesis of 1,3,5-trisubstituted pyrazoles'20016,245,914'Efficient method for the conversion of nitriles to amidines and species thereof'20016,194,569'Efficient process for the preparation of [S-(R,S)]-N-[1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2[4-[4-methyl-1-piper azinyl)carbonyl]phenoxy]-4-oxo-1-azetidine carboxamide, a human leukocyte elastase inhibitor'20016,087,359'Thioaryl sulfonamide hydroxamic acid compounds'20005,985,872'2-amino-benzoxazinones for the treatment of viral infections'19995,962,693'Efficient method for the conversion of nitriles to amidines'19995,945,425'Method of using (H.sup.+ /K.sup.+)ATPase inhibitors as antiviral agents'19995,932,749'Asymmetric synthesis of R-.alpha.-propyl-piperonyl amine and its analogs'19995,856,525'Asymmetric R and S warfarin and its analogs'19995,686,631'Asymmetric synthesis of R and S warfarin and its analogs'19975,583,147'Amides for the treatment of atherosclerosis'1996

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1996–2002Based in Newark, DE, US· patent location history
2001–2020Based in Hockessin, DE, US· patent location history
2006–2020Patents assigned to RIGEL PHARMACEUTICALS INC (120)· patent assignee history
2006–2017Based in Millbrae, CA, US· patent location history
2009–2020Based in Santa Clara, CA, US· patent location history
2012–2020Patents assigned to LI HUI (45)· patent assignee history
2012–2020Patents assigned to SINGH RAJINDER (39)· patent assignee history
2012–2020Patents assigned to ARGADE ANKUSH (25)· patent assignee history
2012–2020Patents assigned to BHAMIDIPATI SOMASEKHAR (25)· patent assignee history
2012–2019Based in Carlsbad, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
RIGEL PHARMACEUTICALS INC1202006–2020
LI HUIself452012–2020
SINGH RAJINDER392012–2020
ARGADE ANKUSH252012–2020
BHAMIDIPATI SOMASEKHAR252012–2020
Locations
LocationPatentsSpan
Santa Clara, California, US912009–2020
Millbrae, California, US322006–2017
Hockessin, Delaware, US252001–2020
Carlsbad, California, US72012–2019
Newark, Delaware, US71996–2002